Astrotech Corporation (ASTC) — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2020, with comparison to fiscal 2019. The request metadata says “2018 Q4,” but the supplied filing is for fiscal 2020.
Business context
Astrotech is commercializing platform mass-spectrometry technology through subsidiaries focused on security detection (1st Detect), agricultural process monitoring (AgLAB), and breath analysis (BreathTech). 1st Detect’s TRACER 1000 has European Civil Aviation Conference certification and had initial commercial sales. AgLAB launched the AgLAB-1000-D2; BreathTech’s BreathTest-1000 remained under development.
Financial performance and liquidity
| Metric (USD millions, except percentages and per-share data) | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0.488 | $0.127 |
| Gross profit / gross margin | $0.039 / 8% | $0.037 / 29% |
| Operating expenses | $8.153 | $8.454 |
| Operating loss | $(8.114) | $(8.417) |
| Net loss | $(8.311) | $(7.534) |
| Net loss per share | $(1.31) | $(1.53) |
| Cash used in operating activities | $(6.931) | $(8.475) |
| Cash and cash equivalents at year-end | $3.349 | $1.588 |
| Working capital | $0.3 | $1.9 |
Revenue rose 284%, primarily from TRACER 1000 sales to one global shipping and logistics customer, which represented substantially all FY2020 revenue. Gross margin fell as units used inventory acquired at research-and-development pricing; management expected material costs to improve with scale. SG&A and R&D declined modestly, while interest and other expense shifted to $197,000 from $25,000 of income.
Total assets were $5.930 million and total liabilities were $5.305 million at June 30, 2020; stockholders’ equity was $625,000, below Nasdaq’s $2.5 million continued-listing equity threshold. Debt included $2.5 million of secured related-party notes bearing 11% interest and a $542,000 PPP note bearing 1% interest. The related-party notes’ maturity was extended after year-end to September 5, 2021. PPP forgiveness was subject to SBA approval.
Financing activities provided $8.692 million in FY2020, including related-party borrowing, equity offerings, and PPP proceeds. The two March 2020 registered offerings raised approximately $5.65 million net and increased share count. Cash at June 30, 2020 was expected to fund operations into the second quarter of fiscal 2021.
Material changes, outlook, and risks
- Net loss increased by $777,000 year over year despite lower operating expenses; revenue remained small relative to operating costs.
- Management and the auditor disclosed substantial doubt about the company’s ability to continue as a going concern. Management was evaluating asset or company sales, licensing, debt or equity financing, mergers, and strategic partnerships; no outcome was assured.
- COVID-19 delayed TSA certification work and disrupted parts of the supply chain, while lower air traffic reduced near-term demand for airport screening equipment. TSA passenger-checkpoint certification testing was on indefinite hold; cargo testing was resuming or expected to resume.
- BreathTest-1000 had not undergone clinical testing. FDA classification and clearance or authorization requirements were unresolved, and an EUA application had not been submitted. The company’s stated approximately 60-second screening capability was a development target, not an established commercial result.
- Since April 2020, SEC staff had conducted an informal, non-public fact-finding inquiry concerning March press releases about BreathTest-1000, the March stock offerings, and related matters. The company said it was cooperating; the inquiry itself was not an indication of a violation.
- After year-end, Astrotech terminated its Austin office lease. It estimated an approximately $552,000 income-statement impact and approximately $1.2 million of savings over the original lease term.
- No specific financial guidance was provided. The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Available liquidity, cash runway, financing progress, and the company’s ability to address the going-concern uncertainty and Nasdaq equity deficiency.
- TRACER 1000 customer orders, revenue quality and repeat sales, customer concentration, gross margins, and the status and timing of TSA cargo certification.
- BreathTest-1000 development evidence, clinical plans, FDA classification and authorization pathway, and any developments in the SEC inquiry.
- Debt terms, collateral and repayment obligations, the SBA’s decision on PPP forgiveness, and the effect of further borrowing or equity issuance on dilution.
- The full independent auditor’s report and the reported lease-termination accounting and savings. The supplied filing text’s auditor-opinion passage appears to describe the 2019 statements, so the report scope should be confirmed against the filed document.